1️⃣ Isomorphic bought itself a clinical clock Isomorphic Labs raised a $2.1 billion Series B led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund in the round.
💡 Why it matters AI drug discovery is now being financed like platform biotech. The next proof point is not another model demo, but assets moving toward the clinic.
☕ Coffee talk At $2.1 billion, how long does the market wait before asking for human data?
2️⃣ Kyverna crossed the first autoimmune CAR-T gate Kyverna initiated a rolling BLA for miv-cel in stiff person syndrome after FDA alignment that the single-arm KYSA-8 trial can support the filing.
💡 Why it matters This removes a real regulatory overhang for the first autoimmune CAR-T file and turns Kyverna from data story into launch-readiness story.
☕ Coffee talk If one SPS file works, who else starts treating autoimmune CAR-T as a regulatory category?
3️⃣ Valneva cut for the Lyme window Valneva cut 2026 product sales guidance to €135 million-€150 million and plans to reduce its workforce by 10%-15%, while Pfizer is expected to file the Lyme vaccine.
💡 Why it matters The travel-vaccine base is not carrying the story cleanly. VLA15 is becoming the strategic bridge, not just the next pipeline event.
☕ Coffee talk If travel vaccines cannot fund the bridge, how much does the Pfizer Lyme file have to carry?